Table 1.
Baseline characteristics and frequency of eight targetable genomic alterations of 3115 NSCLC patients from the DFCI cohort according to tumor histology
| DFCI cohort | Adenocarcinoma | Squamous cell carcinoma | Lung carcinoid | Large cell carcinoma | Adenosquamous carcinoma | Othera | Total | |
|---|---|---|---|---|---|---|---|---|
| Age at diagnosis | Median | 66 | 68 | 58.5 | 64 | 67 | 65.5 | 66 |
| Sex | Male (%) | 883 (36.9%) | 204 (60.5%) | 16 (22%) | 10 (42%) | 8 (53%) | 135 (50%) | 1256 (40.4%) |
| Female (%) | 1512 (63.1%) | 133 (39.5%) | 58 (79%) | 14 (58%) | 7 (47%) | 135 (50%) | 1859 (59.6%) | |
| Site | Primary (%) | 1400 (58.5%) | 244 (72.4%) | 62 (84%) | 13 (54%) | 14 (93%) | 133 (49.3%) | 1866 (59.9%) |
| Metastasis (%) | 910 (38.0%) | 77 (22.8%) | 11 (15%) | 11 (46%) | 1 (7%) | 111 (41.1%) | 1121 (36.0%) | |
| Local Recurrence (%) | 36 (1.5%) | 9 (2.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (1.9%) | 48 (1.5%) | |
| Unspecified (%) | 49 (2.0%) | 7 (2.1%) | 1 (1%) | 0 (0%) | 0 (0%) | 21 (7.8%) | 80 (2.6%) | |
| Smoking status | Current (%) | 375 (15.7%) | 91 (27.0%) | 3 (4%) | 8 (33%) | 2 (13%) | 52 (19.3%) | 531 (17.0%) |
| Former (%) | 1420 (59.3%) | 214 (63.5%) | 36 (49%) | 12 (50%) | 11 (74%) | 170 (63.0%) | 1863 (59.8%) | |
| Never (%) | 600 (25.0%) | 32 (9.4%) | 35 (48%) | 4 (16%) | 2 (13%) | 48 (17.8%) | 721 (23.1%) | |
| Targetable alterations | EGFRL858R/exon19del/exon20ins (%) | 429 (17.9%) | 3 (0.9%) | 0 (0%) | 0 (0%) | 3 (20%) | 20 (7.4%) | 455 (14.6%) |
| KRASG12C (%) | 367 (15.3%) | 7 (2.1%) | 0 (0%) | 3 (12%) | 0 (0%) | 28 (10.4%) | 405 (13.0%) | |
| MET amp/exon14skipping (%) | 108 (4.5%) | 5 (1.5%) | 0 (0%) | 1 (4%) | 2 (13%) | 12 (4.4%) | 128 (4.1%) | |
| BRAFV600E (%) | 51 (2.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (1.9%) | 56 (1.8%) | |
| ALK fusion (%) | 61 (2.5%) | 3 (0.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (3.0%) | 72 (2.3%) | |
| ROS1 fusion (%) | 27 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (1.5%) | 31 (1%) | |
| RET fusion (%) | 35 (1.5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.7%) | 37 (1.2%) | |
| NTRK fusion (%) | 3 (0.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.4%) | 4 (0.1%) | |
| Total | N (% of total samples) | 2395 (76.9%) | 337 (10.8%) | 74 (2.4%) | 24 (0.8%) | 15 (0.5%) | 270 (8.6%) | 3115 |
a Includes non-small cell lung cancer not otherwise specified (NOS), pleomorphic carcinoma of the lung, neuroendocrine lung carcinoma NOS, sarcomatoid carcinoma of the lung, adenoid cystic carcinoma of the lung, giant cell carcinoma of the lung, spindle cell carcinoma of the lung, inflammatory myofibroblastic lung tumor, basaloid carcinoma of the lung, ciliated muconodular papillary tumor of the lung, and lymphoepithelioma-like carcinoma of the lung